Live Breaking News & Updates on Agilent Dako|Page 10
Stay updated with breaking news from Agilent dako. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Libtayo (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with =50% PD-L1 expression Approval ....
TARRYTOWN, N.Y. and PARIS, June 25, 2021 /PRNewswire/ Approval based on a Phase 3 trial demonstrating Libtayo significantly improved overall survival compared to chemotherapy in advanced. | June 25, 2021 ....
/PRNewswire/ Approval based on a Phase 3 trial demonstrating Libtayo significantly improved overall survival compared to chemotherapy in advanced NSCLC that. ....
/PRNewswire/ Libtayo recommended for approval in the first-line treatment of certain patients with advanced non-small cell lung cancer whose tumors have. ....
Share this article Share this article ResearchAndMarkets.com s offering. As the unfortunate milestone of one full year of the global COVID-19 pandemic worldwide is reached, the diagnostic industry has been changed, perhaps permanently. Hundreds of test products are on the market to detect the virus, both for its presence and immune response. And billions of dollars have been added to the in vitrodiagnostic market. Companies have doubled and tripled revenues, bought new companies, increased manufacturing, shifted focus to infectious diseases and launched new products. New features have been added to tests, such as variant and mutation detection, combination with flu and RSV, more specific [neutralizing] antibody detection, or ultra-large volume capacities. A new category of testing has been created that in a year is rivaling all others in the volume. And with it, the market changes a shift of top categories in IVD towards infectious disease testing and other COV ....